Users Coming Off Anti-Obesity Jabs Put On Weight at a Quadrupled Rate Compared to Dieters

New research reveals that people who stop using popular GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who halt traditional diet and exercise regimens.

Published data in a leading medical journal demonstrates that while obese individuals can lose substantial amounts of their total mass while using the jabs, the mass comes back at an average rate of 0.8 kg per month after stopping.

"Individuals buying these treatments need to be cognizant of the danger of fast rebound weight gain when the medication ends," stated expert Dr. Susan Jebb.

That rate of regain implies a reversion to starting mass in about one and a half years.

Analyzing Treatments

The analysis, which examined 37 of studies involving thousands of participants, contrasted the results of the injectable medications with conventional dieting.

Researchers point out that people who shed pounds through dieting usually have a slower weight regain—around 0.1 kg a month—once they finish.

Explaining the Fast Regain

Nutrition scientists propose the way of the injections accounts for the amplified weight return.

These medications imitate a body's own chemical called GLP-1, which moderates feelings of fullness.

"Long-term administration of the hormone levels far above than the body's typical production could lead to the body to produce less of its own natural hormone, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.

"Stopping of this hormone supplement leads to appetite is uncontrolled, making overeating a significant risk."

A Chronic Disease?

The NHS advise the jabs for individuals with weight-linked medical conditions, alongside prescribed lifestyle changes.

Many experts say that, considering the high risk of weight regain, the treatment might need to be ongoing.

This opinion is supported by drug manufacturers, who say that the findings "emphasize the persistent nature of obesity," akin to managing conditions like diabetes.

Patient Testimonies

Users who have stopped the medication describe a intense resurgence of cravings.

"I experienced something that goes on and you're instantly ravenous," described one woman.

This challenge is exacerbated if patients have not developed lasting lifestyle or habit modifications during treatment.

Growing Use

Recent estimates show that a significant number of people in the UK have tried these injections in the past year, with interest being substantial.

• Use is more common among women compared to males.
• The 40s and 50s age group shows the greatest level of interest.
• A large proportion access the drugs through private healthcare rather than the NHS.

In conclusion, researchers emphasize that while these medications are powerful tools for shedding pounds, they are not a permanent solution and maintained weight loss relies on integrated lifestyle changes.